Teva cuts sales guidance amid competitive pressures, currency exchange woes

As Teva grapples with competitive pressures and currency exchange woes, the company posted a sizable sales decline in the first quarter.

The Israeli generics giant reaped revenues of $3.66 billion, down 8% from $3.98 billion during the same period last year. After the performance, the drugmaker cut its revenue guidance for the full year.